Login to Your Account


Biopharma gets its groove back as Q1 approval of NMEs grows

By Peter Winter

Monday, April 17, 2017

It looks as though the biopharmaceutical industry is back on track to make up for its poor return on research investments last year when only 22 new molecular entities (NMEs) received the FDA's green light, the fewest number for five years. In the first quarter of this year, 12 NMEs were approved, outperforming comparable periods since 2013.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription